瑞典制药工业市场前景及投资研究报告-培训课件外文版2024.5

INDUSTRIES

&

MARKETSPharmaceuticalindustryinSwedenCHAPTER

01EuropeancontextPharmaceuticalproductionvalueofEFPIAmembersfrom1990to2022(inmillioneuros)MembersofEFPIA'spharmaceuticalproductionvalue1990-2022400,000350,000300,000250,000340,000323,950290,309259,857250,868248,053238,437221,088216,928213,003199,730200,000150,000100,00050,0000127,50463,0101990200020102012201320142015201620172018202020212022*3Description:ThisstatisticdisplaysthepharmaceuticalproductionvalueofEFPIA(EuropeanFederationofPharmaceuticalIndustriesandAssociations)membersfrom1990to2022.In2022,themembersofEFPIAgeneratedanestimatedpharmaceuticalproductionvalueofsome340billioneuros.ReadmoreNote(s):EuropeSource(s):EFPIA;EurostatPharmaceuticalmarketvalueinselectedEuropeancountriesin2021(inmillioneuros)MarketvalueofpharmaceuticalindustrybyEuropeancountry2021Marketvalueinmillioneuros05,00010,00015,00020,00025,00030,00035,00040,00045,00050,000GermanyFrance47,58832,077UnitedKingdomItaly28,81124,143SpainRussia18,44218,398Poland7,8177,073NetherlandsBelgiumTurkey6,7286,496SwitzerlandGreece6,1275,4685,247Austria4Description:Thisstatisticdisplaysthepharmaceuticalindustry'smarketvalueinEuropebyselectedcountriesin2021.ThepharmaceuticalmarketinDenmarkwasvaluedaround3.4billioneurosinthatyear.Germanywasthetop-rankedpharmaceuticalmarketinEuropeduringthatyearwithavalueofsome47.6billioneuros.ReadmoreNote(s):EuropeSource(s):EFPIA;IQVIAPharmaceuticalresearchanddevelopmentspendinginselectedEuropeancountriesin2021(inmillioneuros)ResearchanddevelopmentinEuropeanpharmaceuticalindustrybycountry2021R&Dspendinginmillioneuros3,000

4,000

5,00001,0002,0006,0007,0008,0009,000GermanySwitzerlandUnitedKingdomBelgium8,5408,2326,8575,196France4,451Italy1,680SpainDenmarkSweden1,2671,1141,104NetherlandsRussia900706PolandIreland3213055Description:ThisstatisticdisplaystheEuropeanpharmaceuticalindustry'sresearchanddevelopmentexpendituresbycountryin2021(orlatestyearavailable).ThepharmaceuticalindustryinDenmarkspentanestimated1.1billioneurosonresearchanddevelopmentinthatyear.ReadmoreNote(s):EuropeSource(s):EFPIAPharmaceuticalproductioninselectedEuropeancountriesin2021(inmillioneuros)ProductioninEuropeanpharmaceuticalindustrybycountry2021Productioninmillioneuros30,000010,00020,00040,00050,00060,00070,000SwitzerlandBelgium59,82343,300GermanyItalyUnitedKingdomFrance34,57934,40027,77223,557Ireland19,305SpainDenmarkSweden17,45716,8199,616RussiaNetherlandsHungary6,4596,1803,6076/statistics/315964/european-pharmaceutical-industry-production-by-select-countriesThisstatisticdisplaystheEuropeanpharmaceuticalindustry'sproductionbyselectedcountriesin2021(orlatestyearavailable).ThepharmaceuticalindustryinSwitzerlandproducedpharmaceuticalproductsworthanestimated59.8billioneurosin2021.ReadmoreNote(s):EuropeSource(s):EFPIAPharmaceuticalemploymentinselectedEuropeancountriesin2021EmploymentinEuropeanpharmaceuticalindustrybycountry2021Numberofemployees020,00040,00060,00080,000100,000120,000140,000GermanyFrance121,24599,310UnitedKingdomItaly70,00067,300SpainSwitzerlandTurkey49,20046,80042,29142,06240,204BelgiumIrelandHungaryRomaniaGreece34,80033,23028,80027,868Denmark7Description:ThisstatisticdepictstheEuropeanpharmaceuticalindustry'semploymentbyselectedcountriesin2021(orlatestyearavailable).ThepharmaceuticalindustryinDenmarkemployednearly28thousandpersonsinthatyear.Thus,Denmarkwasrankedinthemiddlebasedonpharmaceuticalemployees.ReadmoreNote(s):EuropeSource(s):EFPIACHAPTER

02Sales/revenueSalesvalueofpharmaceuticalsinSwedenfrom2013to2022(inmillionSEK)SalesvalueofpharmaceuticalsinSweden2013-202260,00050,00040,00054,27950,23848,70546,41643,14738,35436,98134,60232,84531,46530,00020,00010,000020132014201520162017201820192020202120229Description:ThetotalsalesvalueofpharmaceuticalsinSwedengreweachyearduringtheperiodfrom2013to2022.Thesalesvaluewasaround31.5billionSwedishkronerin2013andincreasedsteadilytoaround54.3billionuntil2022.

ReadmoreNote(s):Sweden;2013to2022;pharmacypurchasingprices,incl.vetSource(s):IQVIA;LäkemedelsindustriföreningenLeading10pharmaceuticalcompaniesinSwedenbysalesin2022(inmillionSEK)ToppharmaceuticalcompaniesinSwedenbysales2022SalesinmillionSEK1,50005001,0002,0002,5003,0003,5003,3464,000Janssen-Cilag(Johnson&Johnson)Bristol-MyersSquibbOrifarm2,7492,345Takeda2,132Merck,Sharp&DohmeNovartis1,7941,6361,4711,3851,2871,263TevaBayerBoehringerIngelheimRoche10Description:ThisstatisticshowstheleadingpharmaceuticalcompaniesinSwedenin2022,bysales.ThecompanywiththehighestpharmarevenueinSwedenwasJohnson&Johnson'ssubsidiaryJanssen-Cilag,generating3.35billionSwedishkronor.SecondrankedwasBristol-MyersSquibb,amountingtosalesof2.75billionSwedishkronor.ReadmoreNote(s):Sweden;2022Source(s):Bonnier(BonnierPharmaInsights);Website(svenskfarmaci.se)RevenueofpharmaceuticalsinSwedenin2022,bytypeofpharmaceutical(inbillionSEK)RevenueofpharmaceuticalsinSwedenbytype20224037353025201510512.74.530SubsidizedprescriptionsPharmaceuticalsforinpatientcareNonprescribedpharmaceuticalsUnsubsidizedprescriptions11Description:ThegroupofsubsidizedprescriptionpharmaceuticalswasthepharmaceuticalcategorythatgeneratedthehighestpharmaceuticalrevenueinSwedenin2022,reaching37billionSwedishkronor.Itwasfollowedbypharmaceuticalsforinpatientcare,whichgeneratedrevenuesof12.7billionSwedishkronor.ReadmoreNote(s):Sweden;2022Source(s):Tandvårds-ochläkemedelsförmånsverketPercapitaexpenditureonsubsidizedpharmaceuticalsinSwedenfrom2010to2022(inSEK)PercapitaexpenditureonsubsidizedpharmaceuticalsinSweden2010-20223,5003,0002,5002,8862,7112,6222,4082,3732,2632,2392,2422,2592,1572,1152,0522,0652,0001,5001,0005000201020112012201320142015201620172018201920202021202212Description:ThepercapitaexpenditureonsubsidizedpharmaceuticalsinSwedenincreasedeveryyearsince2013,whenitamountedto2,052Swedishkronorpercapita.In2022,theexpenditurehadincreasedto2,886Swedishkronorpercapita.

ReadmoreNote(s):Sweden;2010to2022Source(s):SverigeskommunerochregionerSalesvalueofgenericpharmaceuticalsinSwedenfrom2013to2022(inmillionSEK)SalesvalueofgenericpharmaceuticalsinSweden2013-202214,00012,00010,00012,53811,39711,40410,0728,2357,5978,0006,7446,2216,0004,0002,00005,4975,0332013201420152016201720182019*2020*2021*2022*13Description:ThesalesvalueofgenericpharmaceuticalsinSwedenincreasedsteadilyduringtheperiodfrom2013to2022.ThesalesvaluewasaroundfivebillionSwedishkronorin2013,andhadincreasedtoaround12.5billionSwedishkronorin2022.

ReadmoreNote(s):Sweden;2013to2022;*Calculatedbasedongivenfigures.ReadmoreSource(s):IQVIA;LäkemedelsindustriföreningenSalesshareofgenericpharmaceuticalsinSwedenfrom2008to2022SalesshareofgenericpharmaceuticalsinSweden2008-202280%68.3%70%60%50%40%30%20%10%0%66.8%64.7%64.1%62.2%62.3%61.4%59.4%57.3%55.1%52.7%48.7%46.5%44.1%42.4%20082009201020112012201320142015201620172018201920202021202214Description:Theshareoftotalpharmaceuticalsalesthatcamefromgenericsincreasedeachyearduringtheperiodfrom2008to2022.Thesharereachedmorethanhalfofthetotalsalesin2012,andincreaseduptomorethantwothirdsofdefineddailydoses(DDD)dispensedin2021,andfinallyto68.3percentin2022.ReadmoreNote(s):Sweden;2008to2022;basedondefineddailydosesSource(s):IQVIA;LäkemedelsindustriföreningenCHAPTER

03TradeValueofpharmaceuticalsimportedintoSwedenfrom2012to2022(inbillionSEK)ImportvalueofpharmaceuticalsintoSweden2012-20227060504066.151.850.547.340.938.137.73431.130.430.730201002012201320142015201620172018201920202021202216Description:Swedenimportedpharmaceuticalsworthsome66.1billionSwedishkronorin2022,whichwasthehighestimportsvalueofpharmaceuticalsduringtheobservedperiodsince2012.Theimportvaluesovertheseyearsweresignificantlylowerthantheexportvaluesofpharmaceuticals.ReadmoreNote(s):Sweden;2014to2022Source(s):Läkemedelsindustriföreningen;StatisticsSwedenValueofpharmaceuticalexportfromSwedenfrom2012to2022(inbillionSEK)ExportvalueofpharmaceuticalsfromSweden2012-202216014012010080139.4114.8105.410082.274.271.269.459.257.556.360402002012201320142015201620172018201920202021202217Description:TheexportvalueofpharmaceuticalsfromSwedengrewsteadilysince2016.Thehighestvaluewasreachedin2022,whenitwasalmost140billionSwedishkronor.Intheyearbefore,therewasasignificantdrop,whenjustabout100millionkronorworthofexportswerereported.ReadmoreNote(s):Sweden;2014to2022Source(s):Läkemedelsindustriföreningen;StatisticsSwedenNetexportvalueofpharmaceuticalsfromSwedenfrom2012to2022(inbillionSEK)NetexportvalueofpharmaceuticalsfromSweden2012-20228070605073.964.358.148.240.937.24030201003631.728.526.425.92012201320142015201620172018201920202021202218Description:ThenetexportvalueofpharmaceuticalsfromSwedenpeakedsignificantlyin2022,whenthevaluereachedsome74billionSwedishkronor.Thepreviouslyhighestvalueduringtheobservedperiod,from2012to2022,wasin2020,whenthevaluestoodatover64billionSwedishkronor.ReadmoreNote(s):Sweden;2014to2022Source(s):Läkemedelsindustriföreningen;StatisticsSwedenImportshareofpharmaceuticalstoSwedenin2022,bycountryImportshareofpharmaceuticalstoSweden2022,bycountryImportshare0%2%4%6%8%10%12%14%16%18%18%20%GermanyDenmark15%UnitedStatesBelgium13.7%12.2%NetherlandsSpain9.4%5.2%4.6%ItalyFrance3.4%3.3%SwitzerlandOthercountries15.2%19Description:ThelargestimportcountryofpharmaceuticalstoSwedenin2022wasGermany,whichaccountedfor18percentofthetotalpharmaceuticalimportsvaluethatyear.Denmarkwasthesecondlargestimportcountryforpharmaceuticals,andaccountedforaround15percent.ReadmoreNote(s):Source(s):InternationalTradeCentreExportshareofpharmaceuticalsfromSwedenin2022,bycountryExportshareofpharmaceuticalsfromSweden2022,bycountryExportshare0%5%10%15%20%20.2%25%30%35%UnitedStatesofAmericaGermany13.5%China8.6%France5.6%5.6%JapanNorway5.2%Austria3.2%3.1%ItalyRussianFederationOthercountries2.5%32.5%20/statistics/945187/export-share-of-pharmaceuticals-from-sweden-by-countryThelargestexportcountryforSwedishpharmaceuticalsin2022wastheUnitedStates,whichaccountedformorethan20percentofSweden'stotalpharmaceuticalexportsthatyear.Germanyfollowedassecondwith13.5percentoftheexports.

ReadmoreNote(s):Sweden;2022Source(s):InternationalTradeCentreCHAPTER

04NewproductsandR&DNumberofapplicationsforclinicaltrialsinSwedenfrom2014to2021,bysponsorNumberofapplicationsforclinicaltrialsinSweden2014-2021,bysponsorCommercialsponsorsNon-commercialsponsors35030025020015010050869291838398748120019819318918717716114902014201520162017201820192020202122Description:MostoftheapplicationsforpharmaceuticalclinicaltrialsinSwedenduringtheperiodfrom2014to2021camefromcommercialactors.In2021,therewere83applicationsfromnon-commercialactors,and193fromcommercialactors.

ReadmoreNote(s):Sweden;2014to2021;referstoapplicationstotheSwedishMedicalProductsAgencySource(s):EMANumberofpatentsinthebiotechnologysectorinSwedenfrom2011to2020NumberofbiotechnologypatentsinSweden2011-2020160140142139130127124119117116115120100806040200109201120122013201420152016201720182019202023Description:ThenumberofpatentsthatSwedenobtainedwithinthebiotechnologysectorincreasedslightlyfrom2018to2020,from127to142.Thus,2020showedthehighestnumberofpatentsinthebiotechnologysector.

ReadmoreNote(s):Sweden;2011to2020Source(s):OECDNumberofnewmedicinesapprovedbyEMAin2018-2020andavailabilityinSwedenasof2022NewpharmaceuticalsEMAapprovedandavailabilityinSweden202220182019202045394035302520151052422201290SuppliedNotsupplied24Description:Thisstatisticshowsthenumberofnewpharmaceuticals,approvedbytheEuropeanMedicinesAgency(EMA)intheyears2018-2020,andtheiravailabilityinSweden,asof2022.Among46medicinesapprovedbyEMAin2020,onlyaroundhalfofthemweresuppliedinSwedeninMay2022.ReadmoreNote(s):Sweden;asofMay2022;116approvedmedicinesSource(s):Läkemedelsindustriföreningen;QuantifyCHAPTER

05KeyplayersAstraZeneca'srevenuefrom2006to2022(inmillionU.S.dollars)AstraZeneca'srevenue2006-202250,00045,00040,00042,99836,54133,59133,26935,00030,00025,00020,00015,00010,0005,000032,80431,60129,55927,97326,47526,09525,89025,71123,64123,56521,31921,04920,1522006200720082009201020112012201320142015201620172018201920202021202226Description:ThisstatisticshowstherevenueofpharmaceuticalcompanyAstraZenecafrom2006to2022.AstraZenecaplcisoneofthetop10pharmaceuticalcompaniesworldwide(basedonRxdrugrevenue).ThemultinationalcompanyisheadquarteredinLondon,UK.AstraZenecaisfocusedonproductsforfollowingmajordiseaseareas:cancer,cardiovascular,gastrointestinal,infection,neuroscience,respiratoryandinflammation.TogetherwiththeOxfordUniversity,thecompanyalsodeveloped[...]

ReadmoreNote(s):WorldwideSource(s):AstraZenecaTopproductsofAstraZenecabasedonrevenuein2021and2022(inmillionU.S.dollars)AstraZeneca'stopproductsbasedonrevenue2021-2022RevenueinmillionU.S.dollars2022202101,0002,0003,0004,0005,0006,0005,444TagrissoFarxigaSolirisImfinzi5,0154,3813,0003,7621,8742,7842,6382,5382,4122,348LynparzaSymbicortEvusheldCalquenceUltomirisVaxzevriaFasenraBrilinta2,7282,1852,0571,9651,798851,2386883,9171,3961,2581,3581,4721,2851,326NexiumCrestor1,0481,09627Description:AstraZenecaisaglobalbiopharmaceuticalcompanywithseveralleadingpharmaceuticalproducts.Asof2022,AstraZeneca`stoppharmaceuticalproductbyrevenuewasTagrisso,amedicationusedinthetreatmentofnon-small-celllungcarcinomas.Duringthatyear,Tagrissogenerated5.44billionU.S.dollarsinrevenueforthecompany.Thesecond-highestrevenuegeneratorforAstraZenecain2021wasVaxzevria,theCOVID-19vaccine,generatingabout3.9billionU.S.dollars,[...]

ReadmoreNote(s):WorldwideSource(s):AstraZenecaAnnualrevenueofSobifrom2009to2022(inmillionSEK)AnnualrevenueofSobi2009-202220,00018,00018,79015,52916,00015,26114,24814,00012,00010,0008,0006,0004,0002,00009,1396,51120175,20420163,22820152,60720142,17720131,91020111,92320121,29720091,18620102018201920202021202228Description:AnnualrevenuesofSwedishbiopharmacompanySobiincreasedfromaround6.5billionSwedishkronorin2017,uptothehighestvalueofaround18.8billionSwedishkronorin2022.Thecompany'sfullnameisSwedishOrphanBiovitrumAB.Sobiisspecializedonthetreatmentofrarediseases.ThisstatisticillustratestheannualrevenueofSobifrom2009to2022.ReadmoreNote(s):Sweden;2009to2022Source(s):SobiAnnualprofit/lossofSobifrom2009to2022(inmillionSEK)Annualprofit/lossofSobi2009-20223,5003,0002,5002,0001,5001,0005003,3043,2452,6792,6382,4181,1498027183180-105-101-92-270-5002009201020112012201320142015201620172018201920202021202229Description:SwedishbiopharmaceuticalcompanySobimadeannuallossesinsomeyearsbefore2015.However,thecompanymadeprofitswhichincreasedsignificantlysincethen,withapeakin2019ofaround3.3billionSwedishkronor.In2022,profitsamountedtosome2.6billionkroner.Thecompany'sfullnameisSwedishOrphanBiovitrumAB.Sobiisspecializedonthetreatmentofrarediseases.Thisstatisticillus